4. (Original) A pharmaceutical composition according to claim 1, which comprises from about 0.5% to 30% by weight of carboxyvinyl polymer as stabilizer to inhibit the degradation of bupropion hydrochloride.

5. (Previously Amended) A pharmaceutical composition according to claim 1, which comprises from about 0.5% to 30% by weight of carboxyvinyl polymer to provide drug release over a period of from about 8 hours to about 24 hours.

6. (Original) A pharmaceutical composition according to claim 5, which comprises from about 5% to about 30% by weight of the carboxyvinyl polymer.

7. (Original) A pharmaceutical composition according to claim 5, which comprises from about 8% to 28% by weight of carboxyvinyl polymer.

8. (Original) A pharmaceutical composition according to claim 5, which comprises from about 10% to about 28% by weight of carboxyvinyl polymer.

9. (Original) A method of stabilizing bupropion hydrochloride in a pharmaceutical composition according to claim 1, wherein said method comprises mixing bupropion hydrochloride with suitable pharmaceutical excipients and carboxyvinyl polymer and granulating with purified water.

10. (Original) A pharmaceutical composition according to claim 1 further comprising a pharmaceutical excipient selected from the group consisting of lactose, magnesium stearate and microcrystalline cellulose.

11. (Original) A pharmaceutical composition according to claim 10, wherein the pharmaceutical excipient is microcrystalline cellulose.

12. (Currently Amended) A sustained release tablet comprising bupropion hydrochloride and carboxyvinyl polymer and lactose, wherein the carboxyvinyl polymer is the sole stabilizing agent and the sole controlled release material ~~wherein the tablet is substantially free of an acidic pharmaceutical carrier as a stabilizer~~.

13. (Currently Amended) A sustained release tablet comprising bupropion hydrochloride and carboxyvinyl polymer and microcrystalline cellulose, wherein the carboxyvinyl polymer is the sole stabilizing agent and the sole controlled release material ~~wherein the tablet is substantially free of an acidic pharmaceutical carrier as a stabilizer.~~

14. (Original) A sustained release tablet according to claim 12, wherein the mean release of bupropion hydrochloride is one of about between 30% and 45% in 1 hour, about between 60% and 80% in 4 hours, and not less than 85% in 7 hours when tested in distilled water using the United States Pharmacopoeia paddle dissolution method at a rotational speed of 50 rpm.

15. (Original) A sustained release tablet according to claim 13, wherein the mean release of bupropion hydrochloride is one of about between 30% and 45% in 1 hour, about between 60% and 80% in 4 hours, and not less than 85% in 7 hours when tested in distilled water using the United States Pharmacopoeia paddle dissolution method at a rotational speed of 50 rpm.

16. (Original) A sustained release tablet according to claim 12, wherein the mean release of bupropion hydrochloride is one of about between 10% and 25% in 1 hour, about between 30% and 60% in 8 hours, and not less than 65% in 12 hours when tested in distilled water using the United States Pharmacopoeia paddle dissolution method at a rotational speed of 50 rpm.

17. (Original) A sustained release tablet according to claim 13, wherein the mean release of bupropion hydrochloride is one of about between 10% and 25% in 1 hour, about between 30% and 60% in 8 hours, and not less than 65% in 12 hours when tested in distilled water using the United States Pharmacopoeia paddle dissolution method at a rotational speed of 50 rpm.